Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Sales of Lilly's diabetes treatment Mounjaro and weight loss counterpart Zepbound were hurt in the quarter as U.S. pharmaceutical wholesalers whittled inventory they had built up in previous quarters.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Sales of Lilly's diabetes treatment Mounjaro and weight loss counterpart Zepbound were hurt in the quarter as U.S. pharmaceutical wholesalers whittled inventory they had built up in previous quarters.

Sales of Lilly’s diabetes treatment Mounjaro and weight loss counterpart Zepbound were hurt in the quarter as U.S. pharmaceutical wholesalers whittled inventory they had built up in previous ...

Today’s big story – Massive volume of earnings, Alphabet a bright spot on Cloud and AI, AMD missed and pressured semis, Eli ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound. Nevertheless, the stock seems expensive — also when compared to Novo Nordisk ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...